IP Library Granted Patent US 7,790,725
Granted Patent B2
US 7,790,725 · App. 11/774,941 · Granted Sep 7, 2010

Thiazolidine derivatives and medicinal use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,790,725
App. No.
11/774,941
Granted
Sep 7, 2010
Kind
B2
Abstract

A thiazolidine derivative represented by the formula (I) wherein each symbol is as defined in the specification, and a pharmaceutically acceptable salt thereof exhibit a potent DPP-IV inhibitory activity, and can be provided as an agent for the prophylaxis or treatment of diabetes, an agent for the prophylaxis or treatment of obesity and the like.

Claims (68)

1. A thiazolidine derivative represented by the formula (I):

wherein X is a substituent of the following formula:

wherein

m is an integer of 1,

is a single bond or a double bond,

A is a carbon atom or a nitrogen atom,

wherein i) when A is a carbon atom, then A is optionally substituted by a hydroxyl group, carboxy or alkoxycarbonyl, and ii) when A is a nitrogen atom, then

is a single bond, and

Q is aryl or heteroaryl selected from the compounds represented by the following formulas (II)-(XII):

wherein

(i) in the formula (II), 1 to 3 from a, b, c and d is(are) nitrogen atom(s) and the rest is(are) carbon atom(s) or all of them are nitrogen atoms,

R 1a is alkyl, phenyl, pyridyl, pyrimidinyl, imidazolyl or oxazolyl, wherein these groups are optionally substituted by one or more from alkyl, alkoxy, halogen and cyano,

R 2a is a hydrogen atom, alkyl or haloalkyl,

wherein

(i-1) when b is a nitrogen atom, then R 2a is not present,

(i-2) when c and d are both nitrogen atoms, a and b are both carbon atoms, R 1a is phenyl and R 2a is alkyl, then R 1a has one or more substituents mentioned above,

(i-3) when a and d are both nitrogen atoms, b and c are both carbon atoms and R 1a is phenyl without substituent, then R 2a is alkyl or haloalkyl, and

(i-4) when all of a, b, c and d are nitrogen atoms and R 1a is phenyl, then (1) A of the formula (I-b) is a carbon atom and R 1a does not have the above-mentioned substituent, or (2) R 1a is substituted by one or more from alkyl and halogen,

(ii) in the formula (III), one of e and f is a nitrogen atom and the other is a carbon atom, or both are carbon atoms, and

R 3 and R 4 may be the same or different and each is a hydrogen atom, alkyl, phenyl or pyridyl,

(iii) in the formula (IV), j is a sulfur atom, an oxygen atom or a nitrogen atom,

h and i may be the same or different and each is a nitrogen atom or a carbon atom,

R 5 and R 7 may be the same or different and each is a hydrogen atom, phenyl or pyridyl (when h is a nitrogen atom, then R 7 is absent), and

R 6 is a hydrogen atom or alkyl (when i is a nitrogen atom, then R 6 is absent),

(iv) in the formula (V), k, l and n′ may be the same or different and each is a carbon atom or a nitrogen atom, wherein at least one is a carbon atom,

R 8 is a hydrogen atom, phenyl, pyridyl or nitro (when n′ is a nitrogen atom, then R 8 is absent),

R 8a is a hydrogen atom or phenyl,

R 9 is a hydrogen atom, haloalkyl or cyano, and

R 10 is a hydrogen atom or cyano (when 1 is a nitrogen atom, then R 10 is absent),

wherein

(iv-1) when k and n′ are both nitrogen atoms, (1) A of the formula (I-b) is a nitrogen atom, and R 8a , R 9 and R 10 are all hydrogen atoms, or (2) R 8a is phenyl and R 9 is haloalkyl,

(iv-2) when k, l and n′ are all carbon atoms, then R 8 is phenyl or pyridyl,

(iv-3) when k is a nitrogen atom and 1 and n′ are both carbon atoms, (1) R 8 is phenyl or nitro, or (2) R 9 is cyano, and

(iv-4) when 1 is a nitrogen atom, then one of k and n′ is a nitrogen atom,

(v) in the formula (VI), p is a nitrogen atom or a carbon atom,

R 11 is a hydrogen atom, phenyl or pyridyl (when p is a nitrogen atom, then R 11 is phenyl or pyridyl),

R 12 is a hydrogen atom or alkyl (when p is a nitrogen atom, then R 12 is absent), and

R 13 and R 14 are both hydrogen atoms, or when one of them is a hydrogen atom, then the other is cyano, alkoxy or halogen,

(vi) in the formula (VII), one of r and s is a nitrogen atom and the other is a carbon atom,

R 15 is a hydrogen atom, alkyl or phenyl (when r is a nitrogen atom, then R 15 is absent),

R 16 is a hydrogen atom or alkyl (when s is a nitrogen atom, then R 16 is absent), and

R 17 is a hydrogen atom, haloalkyl or cyano,

(vii) in the formula (VIII), r′ and s′ may be the same or different and each is a carbon atom or a nitrogen atom, wherein at least one of them is a nitrogen atom,

R 15a is a hydrogen atom, alkyl or phenyl (when r′ is a nitrogen atom, then R 15a is absent),

R 16a is a hydrogen atom or alkyl (when r′ and s′ are both nitrogen atoms, then R 16a is a hydrogen atom), and

R 17a is a hydrogen atom, haloalkyl or cyano,

(viii) in the formula (IX), t is a sulfur atom or an oxygen atom,

u is a carbon atom or a nitrogen atom, and

R 18 and R 19 are both hydrogen atoms, or one of them is a hydrogen atom and the other is cyano, alkoxy or halogen,

wherein

(viii-1) when u is a carbon atom, then one of R 18 and R 19 is cyano, alkoxy or halogen,

(viii-2) when t is a sulfur atom, then A in the formula (I-b) is a carbon atom, R 19 is a hydrogen atom and R 18 is methoxy or cyano,

(viii-3) A in the formula (I-b) is a nitrogen atom, t is an oxygen atom, R 19 is a hydrogen atom, and when u is a carbon atom, then R 18 is alkoxy or halogen, and

(viii-4) A in the formula (I-b) is a carbon atom, R 19 is a hydrogen atom, u is a carbon atom, and when t is an oxygen atom, R 18 is halogen,

(ix) in the formula (X), v, w, x and y may be the same or different and each is a carbon atom or a nitrogen atom, wherein at least two are carbon atoms,

R 20 , R 21 , R 22 , R 23 , R 24 , R 25 and R 26 may be the same or different and 1 to 3 is(are) haloalkyl, methoxy, ethoxy, isopropoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, hydroxy, cyano or halogen, and the rest is(are) hydrogen atom(s) (when v is a nitrogen atom, then R 20 is absent, when w is a nitrogen atom, then R 22 is absent, when x is a nitrogen atom, then R 23 is absent, when y is a nitrogen atom, then R 25 is absent),

wherein

(ix-1) when v is a nitrogen atom and w, x and y are all carbon atoms, then R 22 is haloalkyl,

(ix-2) when v and w are both nitrogen atoms and x and y are both carbon atoms, then R 21 is cyano, and

(ix-3) when w is a nitrogen atom and v, x and y are all carbon atoms, then (1) R 21 is a hydrogen atom and R 20 is cyano, (2) R 21 is haloalkyl and R 23 is hydroxy, ethoxy, isopropoxy, trifluoromethoxy or 2,2,2-trifluoroethoxy, (3) R 21 is haloalkyl and R 23 and R 25 are both methoxy, (4) R 21 is haloalkyl and R 24 is hydroxy, chloro or trifluoromethyl, (5) R 21 is haloalkyl and R 25 is hydroxy or trifluoromethoxy, (6) R 21 is haloalkyl and R 26 is methoxy, or (7) R 21 is cyano and R 23 is methoxy, and

(x) in the formula (XI), R 27 and R 28 may be the same or different and each is haloalkyl or alkoxy;

Y is methylene, hydroxymethylene, a sulfur atom, sulfinyl or sulfonyl; and

Z is a hydrogen atom or cyano;

wherein when X is a substituent represented by the formula (I-a), then Z is a hydrogen atom, or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the thiazolidine derivative of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmacologically acceptable carrier.

3. A method of inhibiting DPP-IV, which method comprises administering the thiazolidine derivative of claim 1 or a pharmaceutically acceptable salt thereof to a patient in need thereof, whereupon DPP-IV is inhibited.

4. A method of treating type 2 diabetes, which method comprises administering the thiazolidine derivative of claim 1 or a pharmaceutically acceptable salt thereof to a patient in need thereof, whereupon type 2 diabetes is treated.

5. A method of treating obesity, which method comprises administering the thiazolidine derivative of claim 1 or a pharmaceutically acceptable salt thereof to a patient in need thereof, whereupon obesity is treated.

Assignments (1)
CHANGE OF NAME Recorded Apr 17, 2008
From: MITSUBISHI PHARMA CORPORATION
To: MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 020838/0701 →